HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.
Malignant mesothelioma (MM), a rare form of cancer is often associated with previous exposure to fibrous minerals, such as asbestos. Asbestos exposure increases HER1-activity and expression in pre-clinical models. Additionally, HER1 over-expression is observed in the majority of MM cases. In this st...
Main Authors: | Tapan K Nayak, Kayhan Garmestani, Diane E Milenic, Kwamena E Baidoo, Martin W Brechbiel |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-03-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3064677?pdf=render |
Similar Items
-
Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab
by: Diane E. Milenic, et al.
Published: (2017-08-01) -
Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab
by: Mareike Voigt, et al.
Published: (2012-11-01) -
Bench to Bedside: Stability Studies of GMP Produced Trastuzumab-TCMC in Support of a Clinical Trial
by: Diane E. Milenic, et al.
Published: (2015-07-01) -
T86
by: N. Barlev, et al.
Published: (2015-11-01) -
Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
by: Maria Ignez Freitas Melro Braghiroli, et al.
Published: (2024-01-01)